BioSpace News Archive

Cerecor Inc., a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, announced first quarter results for 2020.

AmerisourceBergen Corporation reported that in its fiscal year 2020 second quarter ended March 31, 2020, revenue increased 9.5 percent to $47.4 billion.

New high-volume production test allows Biomerica to expand international distribution to better meet demand of its 10-minute test for coronavirus exposure. The test can be performed anywhere by trained professionals, e.g. airports, schools, work, doctor’s office utilizing blood from a finger prick.

Merck, known as MSD outside the United States and Canada, announced that Frank Clyburn, executive vice president and chief commercial officer, is scheduled to participate in a virtual fireside chat at the BofA Securities 2020 Health Care Conference on May 12, 2020, at 3:40 p.m. EDT.

ASCO Plenary Session to Feature Phase 3 Data for KEYTRUDA® (pembrolizumab) in MSI-H/dMMR Colorectal Cancer

Precision BioSciences, Inc., a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS® genome editing platform, announced that it will report financial results for the first quarter of 2020 on May 15, 2020.

DSTAT Explored as a Potential Novel Treatment for the Current Pandemic While an NDA is Being Prepared for Brincidofovir to Address a Potential Future Pandemic

Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system diseases, reported financial results for its fiscal 2020 second quarter.

Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, announced its financial results and business highlights for the first quarter ended March 31, 2020.

TNX-1810, TNX-1820 and TNX-1830 are Designed to Express Protein Antigens from SARS-CoV-2 That are Different from TNX-1800, Which is Designed to Express Spike Protein